Movement Alert｜Definium Therapeutics Rises 5.04% in Regular Trading, Buoyed by Phase 3 Success and $805M Offering Completion

Market Focus06-30 22:04

On June 30, Definium Therapeutics rose 5.04% in regular trading, trading at $48.63 per share, with turnover of $22.16 million. The rally follows a cluster of positive catalysts in recent sessions.

On June 22, the company announced that its lead candidate DT120 orally disintegrating tablet achieved positive topline results in the pivotal Phase 3 EMERGE study for major depressive disorder, meeting its primary endpoint with statistically significant and clinically meaningful improvement over placebo. On June 26, Definium closed an upsized public offering of approximately 23.7 million common shares at $34 each, raising gross proceeds of $805 million, with underwriters exercising their overallotment option in full — reflecting strong institutional demand. Proceeds are earmarked for R&D, potential commercialization preparation for DT120 ODT, and general corporate purposes. Additionally, RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121673904?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 22:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121673904","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Definium Therapeutics Rises 5.04% in Regular Trading, Buoyed by Phase 3 Success and $805M Offering Completion","media":"Market Focus","content":"<p><p>On June 30, Definium Therapeutics rose 5.04% in regular trading, trading at $48.63 per share, with turnover of $22.16 million. The rally follows a cluster of positive catalysts in recent sessions.</p><p>On June 22, the company announced that its lead candidate DT120 orally disintegrating tablet achieved positive topline results in the pivotal Phase 3 EMERGE study for major depressive disorder, meeting its primary endpoint with statistically significant and clinically meaningful improvement over placebo. On June 26, Definium closed an upsized public offering of approximately 23.7 million common shares at $34 each, raising gross proceeds of $805 million, with underwriters exercising their overallotment option in full — reflecting strong institutional demand. Proceeds are earmarked for R&D, potential commercialization preparation for DT120 ODT, and general corporate purposes. Additionally, RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Definium Therapeutics Rises 5.04% in Regular Trading, Buoyed by Phase 3 Success and $805M Offering Completion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Definium Therapeutics Rises 5.04% in Regular Trading, Buoyed by Phase 3 Success and $805M Offering Completion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-30 22:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 30, Definium Therapeutics rose 5.04% in regular trading, trading at $48.63 per share, with turnover of $22.16 million. The rally follows a cluster of positive catalysts in recent sessions.</p><p>On June 22, the company announced that its lead candidate DT120 orally disintegrating tablet achieved positive topline results in the pivotal Phase 3 EMERGE study for major depressive disorder, meeting its primary endpoint with statistically significant and clinically meaningful improvement over placebo. On June 26, Definium closed an upsized public offering of approximately 23.7 million common shares at $34 each, raising gross proceeds of $805 million, with underwriters exercising their overallotment option in full — reflecting strong institutional demand. Proceeds are earmarked for R&D, potential commercialization preparation for DT120 ODT, and general corporate purposes. Additionally, RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DFTX","symbol_name":"Definium Therapeutics","start_time":0,"source_url":"","article_id":"1121673904","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121673904","pubTimestamp":1782828274,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 30, Definium Therapeutics rose 5.04% in regular trading, trading at $48.63 per share, with turnover of $22.16 million. The rally follows a cluster of positive catalysts in recent sessions.On...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DFTX":"Definium Therapeutics"},"translate_title":"动态警报|Definium Therapeutics在常规交易中上涨5.04%，受第三阶段成功和8.05亿美元发行完成的提振","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DFTX":1},"content_text":"On June 30, Definium Therapeutics rose 5.04% in regular trading, trading at $48.63 per share, with turnover of $22.16 million. The rally follows a cluster of positive catalysts in recent sessions.On June 22, the company announced that its lead candidate DT120 orally disintegrating tablet achieved positive topline results in the pivotal Phase 3 EMERGE study for major depressive disorder, meeting its primary endpoint with statistically significant and clinically meaningful improvement over placebo. On June 26, Definium closed an upsized public offering of approximately 23.7 million common shares at $34 each, raising gross proceeds of $805 million, with underwriters exercising their overallotment option in full — reflecting strong institutional demand. Proceeds are earmarked for R&D, potential commercialization preparation for DT120 ODT, and general corporate purposes. Additionally, RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121673904","isCrawlerRequest":true}